Obesity

Metamodix is focused on developing drug-free, nonsurgical device therapies to address metabolic diseases such as type 2 diabetes, obesity and NASH.

​​Type 2 diabetes

Nonalcoholic steatohepatitis (NASH) affect nearly 100 million people in the US and mirrors the rising trend of obesity. The disease is estimated to cost the US healthcare system over $30 billion dollars annually.

Type 2 Diabetes Mellitus (T2DM) is the fastest growing chronic disease in the world today.  It is estimated that more than 380 million people worldwide suffer from the effects of T2DM and the number is projected to increase to over 592 million by 2035.

Diabetes is also associated with a wide range of serious medical conditions.  Diabetes is the leading cause of cause of blindness, kidney failure and limb amputations in adults. 

According to the American Diabetes Association, the annual cost of treating T2DM in the US alone is $245 billion, which represents 1 in 10 healthcare dollars.  This translates to an average of $9,500 in direct costs, per patient per year.

Worldwide, the number of obese people has increased dramatically, nearly doubling in just the past 30 years.  Recent studies have shown that more than 200 million men and nearly 300 million women are obese.

Obesity is the fifth leading risk for global deaths.  In addition, a significant percentage of those who are obese deal with an increased burden from diabetes, heart disease, and certain cancers.


Each year, more than $140 billion is spent in the US on healthcare costs associated with obesity.  Obese adults spend 42 percent more on direct healthcare costs than adults who are a healthy weight.

NASH